Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-08-25 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Regulatory Filings Classification · 95% confidence The document is a press release from Valneva SE announcing a significant regulatory action by the FDA (suspension of a vaccine license). It details the reasons for the suspension, the company's response, and potential financial implications. This type of announcement regarding regulatory status and its impact on business operations falls under the 'Regulatory Filings' category as it is a general corporate announcement that does not fit into more specific categories like earnings releases or legal proceedings reports.
2025-08-25 English
6-K
Regulatory Filings
2025-08-18 English
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Regulatory Filings Classification · 95% confidence The document is a press release issued by Valneva SE announcing that Health Canada has granted marketing authorization for their vaccine, IXCHIQ®. It follows the standard format of a corporate press release, including a headline, date, quotes from management, background information on the product and company, and a disclaimer regarding forward-looking statements. Since it is a general regulatory announcement regarding product approval that does not fit into more specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-08-18 English
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus
Regulatory Filings Classification · 95% confidence The document is a press release issued by Valneva SE announcing that Health Canada has granted marketing authorization for their chikungunya vaccine, IXCHIQ, for individuals aged 12 and older. It follows the standard format of a corporate press release, including a headline, date, company boilerplate, contact information, and a disclaimer regarding forward-looking statements. Since this is a general regulatory announcement regarding product approval that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS).
2025-08-18 French
6-K
Regulatory Filings
2025-08-12 English
VALNEVA : Rapport Semestriel 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Semestriel' (Half-Year Report) for the period of January 1 to June 30, 2025, for Valneva SE. It contains a detailed activity report, financial statements (consolidated interim financial statements), notes to the financial statements, and an audit report on the interim financial information. This document is a comprehensive financial report for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-12 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.